News | ECG Monitoring Services | May 09, 2018

Online ECG Monitoring Detects Paroxysmal AFib More Effectively Than Holter, Patch Methods

Findings presented at the 2018 Heart Rhythm Society annual scientific sessions

Online ECG Monitoring Detects Paroxysmal AFib More Effectively Than Holter, Patch Methods

May 9, 2018 – Medicalgorithmics S.A. will present the results of a large study evaluating online versus offline electrocardiogram (ECG) monitoring methods to detect paroxysmal atrial fibrillation (PAF), examining the relationship between monitoring duration and diagnostic yield. The study showed diagnostic yield was significantly higher with the PocketECG online monitoring system than with fixed 24 and 48-hour holter and multi-day patch methods. Results will be presented at the 2018 Heart Rhythm Society (HRS) annual scientific sessions, May 9-12 in Boston.

“Paroxysmal atrial fibrillation is an arrhythmia that is often difficult to detect because of its episodic nature but presents real health risks to patients,” said Marek Dziubinski, Ph.D., lead author and inventor of the PocketECG mobile arrhythmia monitoring solution. “This large-scale study demonstrated that the ability to shorten or extend monitoring duration based on the ongoing results transmitted by online ECG monitoring technology can improve diagnostic yield over fixed offline methods.”

The study analyzed 16,595 cardiac telemetry reports developed by Medi-Lynx Cardiac Monitoring between Jan. 1 and Dec. 31, 2016. Data was collected using the PocketECG online monitoring system, which transmits full-disclosure ECG signal for up to 30 days. Continuous and fully labeled recordings, lasting between 1 and 30 days (mean duration: 18.1 ± 9.9 days), were captured with PocketECG and used to determine the monitoring duration required to detect the first AF episode for various AF burdens (AFBs). The study then evaluated the impact of monitoring duration on diagnostic yield (DY) in patients with PAF (for AFB ≤ 1 percent and AFB ≤ 10 percent), and analyzed the difference in DY between the online method (up to 30 days) and simulated offline methods (24 and 48 hours Holter and multiday patch).

For AF burden ≤ 1 percent, online monitoring with PocketECG showed:

  • DY 6 times higher than the first 24h of Holter monitoring;
  • DY 3.5 times higher than the first 48h of Holter monitoring;
  • DY higher by 36 % than the first 11 days with the offline patch; and
  • DY higher by 14 % than the first 18 days with the offline patch.

For AF burden ≤ 10 percent, the online method showed:

  • DY 4 times higher than the first 24h of Holter monitoring;
  • DY 2.5 times higher than the first 48h of Holter monitoring;
  • DY higher by 25 % than the first 11 days with the offline patch; and
  • DY higher by 10 % than the first 18 days with the offline patch.

Paroxysmal AF is a form of arrhythmia that is often difficult to diagnose because of its intermittent nature. It can lead to heart-related complications including blood clots, stroke, and heart failure. Left untreated, AF more broadly can double the risk of heart-related death and increase the risk of stroke by as much as five times.

Roughly the size of a smart-phone, the PocketECG remote arrhythmia monitoring device captures and transmits the full-disclosure ECG signal for up to 30 days – providing the onset and offset of every arrhythmia and classifying morphology for every beat. Patient symptoms are recorded on the touch screen of the device and physical activity captured to distinguish between heart rate changes caused by physical activity and those caused by arrhythmia. PocketECG detects complex ventricular and supraventricular arrhythmia including ventricular tachycardia (VT), supraventricular tachycardia (SVT), bigeminies and trigeminies, and diagnoses atrial fibrillation with single-beat accuracy. Results are statistically summarized in full-color holter-style reports delivered straight to the clinicial through a secure online portal.

Read the related content "Movement Toward Simpler, Wearable Cardiac Monitoring."

For more information: www.pocketecg.com

 

Related Content

Medtronic's DiamondTemp Ablation (DTA) system is FDA cleared to treat patients with recurrent, symptomatic paroxysmal atrial fibrillation (AF) and who have been unresponsive to drug therapy. The DiamondTemp system is the first FDA-approved, temperature-controlled, irrigated radiofrequency (RF) ablation system with diamonds currently available to deliver ablations.

Medtronic's DiamondTemp Ablation (DTA) system is FDA cleared to treat patients with recurrent, symptomatic paroxysmal atrial fibrillation (AF) and who have been unresponsive to drug therapy. The DiamondTemp system is the first FDA-approved, temperature-controlled, irrigated radiofrequency (RF) ablation system with diamonds currently available to deliver ablations.

News | Atrial Fibrillation | January 29, 2021
January 29, 2021 — The U.S.
Patients with atrial fibrillation are at far greater risk of a catastrophic COVID outcomes, so steps should be taken to reduce AFib risks in addition to precautions against COVID like making, hand washing and social distancing. Images include an electromap from an AF ablation procedure and a COVID-19 from the CDC. 

Patients with atrial fibrillation are at far greater risk of a catastrophic COVID outcomes, so steps should be taken to reduce AFib risks in addition to precautions against COVID like making, hand washing and social distancing. Images include an electromap from an AF ablation procedure and a COVID-19 from the CDC. 

Feature | Atrial Fibrillation | January 27, 2021 | By John D. Day, M.D., T. Jared Bunch, M.D., and Matthew D. LaPlante
In our most challenging and distressing days, it is nice to think about a post-COVID-19 world. 
ECG with paroxysm correct form of atrial flutter. Getty Images

ECG with paroxysm correct form of atrial flutter. Getty Images

News | Atrial Fibrillation | December 23, 2020
December 23, 2020 — The American College of Cardiology (ACC) and the American Heart Association (AHA) has made two up
The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evaluated the detection of silent, or previously undiagnosed, atrial fibrillation (AF) in moderate-risk individuals using the FDA-cleared Zio by iRhythm ambulatory monitoring patch. The results support the clinical value of early screening and targeted detection in moderate-risk populations. #AHA #AHA20 #AHA2020

The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evaluated the detection of silent, or previously undiagnosed, atrial fibrillation (AF) in moderate-risk individuals using the FDA-cleared Zio by iRhythm ambulatory monitoring patch. The results support the clinical value of early screening and targeted detection in moderate-risk populations.

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 — The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evalu
The Medtronic SEEQ mobile cardiac telemetry system, pictured here, and the Icentia CardioSTAT cardiac rhythm monitoring device both found in reased rates of post-operative atrial fibrillation in the SEARCH-AF trial presented at the American Heart Association annual meeting. #AHA #AHA20 #AHA2020

The Medtronic SEEQ mobile cardiac telemetry system, pictured here, and the Icentia CardioSTAT cardiac rhythm monitoring device both found in reased rates of post-operative atrial fibrillation in the SEARCH-AF trial presented at the American Heart Association annual meeting.

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 — Atrial fibrill...
The Medtronic Arctic Front cryoballoon balloon was used a a front-line treatment of AF in the EARLY-AF trial. It was found to be better than anti-arrhythmic drugs in preventing the recurrence of abnormal heart rhythm (atrial tachyarrhythmia, atrial fibrillation), and improve patient well-being.  #AHA #AHA2020 #AHA20

The Medtronic Arctic Front cryoballoon balloon was used a a front-line treatment of AF in the EARLY-AF trial. It was found to be better than anti-arrhythmic drugs in preventing the recurrence of abnormal heart rhythm (atrial tachyarrhythmia, atrial fibrillation), and improve patient well-being.  

News | Atrial Fibrillation | November 16, 2020
November 16, 2020 – Doctors from the Mo...

The study used cadaver hearts that were images with contrast enhanced MRI and the images used to create a 3-D computation model of the electrical activation in the heart and how it was influenced by adenosine and ablation. Find more images in the original article

News | Atrial Fibrillation | October 08, 2020
October 8, 2020 – People who suffer from persistent atrial fibrillation in the heart may find relief from a new treat